fbpx

Lundbeckfonden Ventures

An evergreen international life science investor

Lundbeckfonden Ventures is an evergreen venture fund investing internationally in life science companies. Our focus is primarily projects and companies with development candidates close to or in clinical development. We are particularly interested in speciality pharma product opportunities and in technology platforms that have demonstrated their value in generating development candidates.

About us

Since 2009, we have invested in 31 companies in USA and Europe and have an active portfolio of around 18 companies representing a broad spectrum of therapeutic fields. Annually we invest 350 to 400 million Danish kroner.

We work internationally and as lead investor when investing in Europe. We are determined to add value to our investments and will involve ourselves actively in our portfolio companies and work in close collaboration with their management and boards.

Investment opportunities

We are seeking experienced and capable management teams that are committed to resolving the sometimes difficult challenges involved in development of drugs aimed at unmet medical needs. A well-defined plan is crucial as is strong and enforceable patent protection and a sound understanding of the relevant markets and their regulatory frameworks.

The starting point for us is a non-confidential presentation or summary of the project or company. If it falls within our strategic focus area, we will be prepared to enter into a confidentiality agreement and evaluate confidential information. Each investment is potentially a long-term commitment and therefore it is important for us to meet the team and get to know you during our evaluation. Consequently, the next step will be to arrange a meeting where we can discuss data, plans and investment proposals. Continued interest will lead to a thorough due diligence exercise before final deal negotiation.

You can send non-confidential information to: ventures@lundbeckfonden.com

Lundbeckfonden Ventures

News

Acacia Pharma Group PLC – Acacia Pharma completes drawdown from €25 million loan facility from Cosmo Pharmaceuticals to support US launches of BARHEMSYS® and BYFAVO™
9. October 2020
Acacia Pharma Group PLC – Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the US
7. October 2020
Enterome announces first patient dosed in Phase 2a trial of sibofimloc in Crohn’s disease
23. September 2020